Safety and Maximum Tolerated Dose (MTD) Study of INNO-206 in Subjects With Advanced Solid Tumors
Status:
Completed
Trial end date:
2012-12-01
Target enrollment:
Participant gender:
Summary
This is a phase 1b open-label study evaluating the preliminary safety and maximum tolerated
dose of a new formulation of INNO-206 administered at doses of 230 mg/m2, 350 mg/m2 and 450
mg/m2 (165, 260, 325 mg/m2 doxorubicin equivalents, respectively) through intravenous
infusion on Day 1 every 21 days for up to 6 cycles.